GLP1R and pancreatitis: Federal Drug Administration (FDA) Adverse Event Reporting System (FAERS) database ranked the top six adverse events for GLP‐1 agents as nausea, vomiting, diarrhea, upper abdominal pain, constipation, and less frequently, pancreatitis [62]—a potentially fatal condition [63].